Nature Reviews Drug Discovery

Papers
(The TQCC of Nature Reviews Drug Discovery is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Engineering precision nanoparticles for drug delivery2925
Natural products in drug discovery: advances and opportunities1858
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)1214
The COVID-19 vaccine development landscape1174
Advances in oligonucleotide drug delivery966
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy886
PROTAC targeted protein degraders: the past is prologue825
Trends in peptide drug discovery737
Antimicrobial host defence peptides: functions and clinical potential722
Noncoding RNA therapeutics — challenges and potential solutions689
Emerging concepts in the science of vaccine adjuvants556
mRNA vaccines for infectious diseases: principles, delivery and clinical translation544
RAS-targeted therapies: is the undruggable drugged?528
Kinase drug discovery 20 years after imatinib: progress and future directions463
Evolution of the COVID-19 vaccine development landscape428
Organs-on-chips: into the next decade421
Targeting inflammation in atherosclerosis — from experimental insights to the clinic415
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing413
Strategies for delivering therapeutics across the blood–brain barrier380
Macrophages as tools and targets in cancer therapy374
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine357
Targeting cancer metabolism in the era of precision oncology351
Radiopharmaceutical therapy in cancer: clinical advances and challenges342
Anti-obesity drug discovery: advances and challenges326
Trends in kinase drug discovery: targets, indications and inhibitor design309
Channelling inflammation: gasdermins in physiology and disease291
FDA approves 100th monoclonal antibody product280
Antisense technology: an overview and prospectus279
B cell depletion therapies in autoimmune disease: advances and mechanistic insights268
Poly(ADP-ribose) polymerase inhibition: past, present and future262
The clinical landscape for AAV gene therapies262
The quest to slow ageing through drug discovery244
Targeting the epigenetic regulation of antitumour immunity244
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics241
Targeted protein degraders crowd into the clinic235
Therapeutically harnessing extracellular vesicles235
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease220
Navigating CAR-T cells through the solid-tumour microenvironment217
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target211
Kinase inhibition in autoimmunity and inflammation207
PI3K inhibitors are finally coming of age205
Base editing: advances and therapeutic opportunities200
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans196
Beyond immune checkpoint blockade: emerging immunological strategies192
Advances in TRP channel drug discovery: from target validation to clinical studies186
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials182
Next-generation influenza vaccines: opportunities and challenges182
The foundations of immune checkpoint blockade and the ipilimumab approval decennial179
Image-based profiling for drug discovery: due for a machine-learning upgrade?179
Therapeutic strategies for thrombosis: new targets and approaches173
Emerging therapeutic opportunities for integrin inhibitors173
Protein arginine methylation: from enigmatic functions to therapeutic targeting168
Advances in covalent drug discovery164
Circadian rhythm as a therapeutic target162
Identification of neoantigens for individualized therapeutic cancer vaccines160
Advances in therapeutic peptides targeting G protein-coupled receptors153
RNA therapeutics on the rise152
Next-generation stem cells — ushering in a new era of cell-based therapies151
Therapeutic strategies targeting FOXO transcription factors151
Pharmacological targeting of endoplasmic reticulum stress in disease146
Function and therapeutic value of astrocytes in neurological diseases139
Antitumour dendritic cell vaccination in a priming and boosting approach139
Advances in targeting ‘undruggable’ transcription factors with small molecules138
Targeting Notch in oncology: the path forward137
2020 FDA drug approvals137
Engineering living therapeutics with synthetic biology130
Drugging p53 in cancer: one protein, many targets127
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities125
Targeting RNA structures with small molecules123
The PROTACtable genome111
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease108
Lipogenesis inhibitors: therapeutic opportunities and challenges107
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies106
Targeting HER2-positive breast cancer: advances and future directions105
The emerging role of mass spectrometry-based proteomics in drug discovery100
Targeting co-stimulatory molecules in autoimmune disease98
Impact of COVID-19 on oncology clinical trials95
Exosome-based candidates move into the clinic91
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials90
A tale of two antiviral targets — and the COVID-19 drugs that bind them88
Therapeutic strategies for COVID-19: progress and lessons learned88
Drugging the efferocytosis process: concepts and opportunities83
Improving target assessment in biomedical research: the GOT-IT recommendations79
Engineering the next generation of cell-based therapeutics78
Immune targets for therapeutic development in depression: towards precision medicine77
The glomerular filtration barrier: a structural target for novel kidney therapies76
Modulating biomolecular condensates: a novel approach to drug discovery76
The promises and perils of psychedelic pharmacology for psychiatry75
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape75
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs74
2021 FDA approvals72
Cancer cell therapies: the clinical trial landscape71
Targeting replication stress in cancer therapy70
Leveraging preclinical models for the development of Alzheimer disease therapeutics69
Top companies and drugs by sales in 201968
Trends in COVID-19 therapeutic clinical trials67
Phenotypic drug discovery: recent successes, lessons learned and new directions66
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation64
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders62
Double setback for ASO trials in Huntington disease62
Immuno-oncology drug development forges on despite COVID-1961
Antibodies to combat viral infections: development strategies and progress60
Soluble ligands as drug targets60
Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating58
Rational combinations of targeted cancer therapies: background, advances and challenges57
Avidity in antibody effector functions and biotherapeutic drug design57
The oncology market for antibody–drug conjugates57
Ligand binding at the protein–lipid interface: strategic considerations for drug design56
What does AlphaFold mean for drug discovery?55
Antibody–drug conjugates come of age in oncology54
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment54
Breaking Eroom’s Law53
Exercise mimetics: harnessing the therapeutic effects of physical activity52
Clinical development times for innovative drugs52
Engineering islets from stem cells for advanced therapies of diabetes52
The RESOLUTE consortium: unlocking SLC transporters for drug discovery52
Gene therapy community grapples with toxicity issues, as pipeline matures51
Restoring IL-2 to its cancer immunotherapy glory50
Clinical trial recovery from COVID-19 disruption47
AI in small-molecule drug discovery: a coming wave?47
Pan-coronavirus vaccine pipeline takes form46
Phase 0/microdosing approaches: time for mainstream application in drug development?45
Addressing cancer’s grand challenges43
The glymphatic system: implications for drugs for central nervous system diseases43
Targeting galectin-driven regulatory circuits in cancer and fibrosis42
The expanding role for small molecules in immuno-oncology42
Modulating gene regulation to treat genetic disorders40
Bispecific antibodies in oncology40
Targeting receptor complexes: a new dimension in drug discovery40
Deuterium in drug discovery: progress, opportunities and challenges39
Harnessing the predictive power of preclinical models for oncology drug development38
Top companies and drugs by sales in 202138
Landscape of cancer cell therapies: trends and real-world data38
Top companies and drugs by sales in 202038
Strategies to access biosynthetic novelty in bacterial genomes for drug discovery37
Emerging principles of cytokine pharmacology and therapeutics35
Opportunities and challenges with microphysiological systems: a pharma end-user perspective34
Digital technologies for medicines: shaping a framework for success34
mRNA flu shots move into trials32
Adoption of organ-on-chip platforms by the pharmaceutical industry32
Base editors hit the clinic32
2022 FDA approvals31
FDA approves fourth CAR-T cell therapy30
Gene-editing pipeline takes off30
Thinking outside the box: non-canonical targets in multiple sclerosis30
Antibody–oligonucleotide conjugates enter the clinic30
Targeting angiogenesis in oncology, ophthalmology and beyond29
Monitoring protein communities and their responses to therapeutics28
VEGFA mRNA for regenerative treatment of heart failure28
FDA approves first BCMA-targeted CAR-T cell therapy28
mRNA vaccines: intellectual property landscape28
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems27
GPR84: an immune response dial?27
Applications of single-cell RNA sequencing in drug discovery and development26
p53 programmes plough on25
First microbiome-based drug clears phase III, in clinical trial turnaround25
Beyond PI3Ks: targeting phosphoinositide kinases in disease25
Remote digital monitoring in clinical trials in the time of COVID-1924
The evolving role of investigative toxicology in the pharmaceutical industry24
Characteristics of expedited programmes for cancer drug approval in China23
The therapeutic potential of targeting regulated non-apoptotic cell death23
Trends in oncology drug innovation in China23
Predictive validity in drug discovery: what it is, why it matters and how to improve it22
The clinical pipeline for cancer cell therapies22
Informing single-arm clinical trials with external controls22
Accelerating antiviral drug discovery: lessons from COVID-1922
FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm22
Trends in the approval of cancer therapies by the FDA in the twenty-first century22
Therapeutic RNA-silencing oligonucleotides in metabolic diseases22
Author Correction: Targeting oxidative stress in disease: promise and limitations of antioxidant therapy21
First de novo deuterated drug poised for approval20
Stemming the tide of drug resistance in cancer19
COVID-19 impact on oncology clinical trials: a 1-year analysis19
Derivatization with fatty acids in peptide and protein drug discovery18
The mRNA vaccine development landscape for infectious diseases18
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders17
Amplifying gene expression with RNA-targeted therapeutics17
Evolution of the market for mRNA technology17
eEF2K: an atypical kinase target for cancer16
ALS antisense drug falters in phase III16
The breast cancer drug market16
Implications of sex-related differences in central nervous system disorders for drug research and development15
HCAR3: an underexplored metabolite sensor15
Using human genetics to improve safety assessment of therapeutics14
BCKDK: an emerging kinase target for metabolic diseases and cancer14
FDA approves second BCMA-targeted CAR-T cell therapy14
FDA rejects NASH drug14
Digital health technologies in clinical trials for central nervous system drugs: an EU regulatory perspective14
RAS-targeted therapies14
The landscape for lipid-nanoparticle-based genomic medicines14
Pyroptosis heats tumour immunity14
PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disorders13
Author Correction: RAS-targeted therapies: is the undruggable drugged?13
The market for ulcerative colitis13
The KRAS crowd targets its next cancer mutations13
Trends in innovative drug development in China13
Integrin-targeted therapies branch out13
Top companies and drugs by sales in 202212
Industrializing engineered autologous T cells as medicines for solid tumours12
Improving data sharing to increase the efficiency of antibiotic R&D12
Novel drug targets in 201912
COVID-19 must catalyse changes to clinical development12
RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape12
Delivering on the promise of protein degraders12
The prostate cancer drug market11
Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook11
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections11
PIP5K1A: a potential target for cancers with KRAS or TP53 mutations11
Author Correction: Trends in kinase drug discovery: targets, indications and inhibitor design10
FDA approves first haemophilia B gene therapy10
Small-molecule discovery through DNA-encoded libraries10
Small activating RNAs lead the charge to turn up gene expression10
Long COVID’s long R&D agenda10
Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing10
LAG3 pushes immuno-oncology’s leading edge10
A future for regulatory science in the European Union: the European Medicines Agency’s strategy10
Immune status could determine efficacy of COVID-19 therapies10
Trispecific antibodies take to the clinic10
RSV vaccines score landmark FDA approvals9
Artificial intelligence for natural product drug discovery9
opnMe.com: a digital initiative for sharing tools with the biomedical research community9
Application of Bayesian approaches in drug development: starting a virtuous cycle9
Comparing development strategies for PD1/PDL1-based immunotherapies9
Orphan drug designation and development in Japan: 25 years of experience and assessment9
Strategies to therapeutically modulate cytokine action9
AAV-based in vivo gene therapy for neurological disorders9
The failure to fail smartly9
Antimalarial drug discovery: progress and approaches8
NfL makes regulatory debut as neurodegenerative disease biomarker8
FDA approves first peanut allergy drug8
Can anti-inflammatory strategies light up the dim depression pipeline?8
Fragment-based screening sees the light8
Transferrin’ across the blood–brain barrier8
Targeted protein degraders: a call for collective action to advance safety assessment8
Evolution of innovative drug R&D in China8
Author Correction: Next-generation influenza vaccines: opportunities and challenges8
FDA approves fifth RNAi drug — Alnylam’s next-gen hATTR treatment8
FDA approves AstraZeneca’s anifrolumab for lupus8
Amgen overcomes historically undruggable target, with FDA nod for first KRAS inhibitor8
The most successful oncology drug portfolios of the past decade7
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases7
Top product forecasts for 20227
Kinase drug discovery 20 years after imatinib7
CDC42BPA/MRCKα: a kinase target for brain, ovarian and skin cancers7
Translational misconceptions7
FDA approves an inhibitor of a novel ‘epigenetic writer’7
First CRISPR therapy seeks landmark approval7
Novel drug targets in 20217
Research on rare diseases: ten years of progress and challenges at IRDiRC7
FDA approves antibody cocktail for Ebola virus7
0.039098978042603